SUPPLEMENT 32
18 SEPTEMBER 2026

L&G HEALTHCARE TECHNOLOGY & INNOVATION UCITS ETF

A sub-fund of Legal & General UCITS ETF Plc, an umbrella investment company with variable capital and segregated liability between its Funds.

This Supplement contains information relating to the L&G Healthcare Technology & Innovation UCITS ETF (the "Fund") which is a separate Fund of Legal & General UCITS ETF Plc (the "Company"). This Supplement forms part of and should be read in the context of, and together with, the Prospectus dated 18 September 2026. If you are in any doubt about the action to be taken or the contents of this Supplement, please consult your stockbroker or other financial adviser. Potential investors should consider the risk factors set out in the Prospectus and in this Supplement before investing in this Fund. An investment in the Fund involves certain risks and may only be suitable for persons who are able to assume the risk of losing their entire investment.

FUND DETAILS

Base Currency	USD.
Investment Approach	Index Tracking – Physical Replication.
Eligible Assets	Equity Securities; Depositary Receipts; FDIs namely, Total Return Swaps, forward currency contracts (including non-deliverable forwards) and Equity Futures; Money Market Funds.
Securities Financing Transactions	Securities Lending: Maximum 45%, Expected 0-20%. Repurchase, Reverse Repurchase and TRS Transactions: Maximum 100%, Expected 0%.
SFDR	Article 9.
Summary of Sustainable Investment Objective	The sustainable investment objective of the Fund is to provide exposure to the global healthcare technology industry. Further information on the sustainable investment objective of the Fund can be found in the Annex.
Index	ROBO Global® Healthcare Technology and Innovation Index TR.
Index Rebalancing	Quarterly, in March, June, September and December.
Index Characteristics	The Index is a Net Total Return Index.
Additional Index Details	Further information on the Index methodology, constituents and weightings can be found here.
TER	Unhedged Classes: 0.49%, Hedged Classes: 0.54%.
Minimum Subscription / Redemption Amount	50,000 Shares.
Initial Offer Price	Approximately USD 10, expressed in the class currency of the relevant class.
Initial Offer Period	Unlaunched Shares in each class will be available at the Initial Offer Price from 9 am UK time on 21 September 2026 to 4:00 pm on 19 March 2027 or such earlier or later date as the Directors may determine and notify to the Central Bank.
Transaction Charges	In respect of each subscription or redemption of Shares, the Manager (or its delegate) may apply Duties and Charges or an Anti-Dilution Levy either as a fixed amount or on an actual cost basis. Any fixed charge shall not exceed 5% of the Net Asset Value of the Shares subscribed for or redeemed.

Capitalised expressions used and not defined in this Supplement shall bear the meanings as set out in the Prospectus.

INVESTMENT OBJECTIVE

The investment objective of the Fund is to provide exposure to the global healthcare technology industry.

INVESTMENT POLICY

In order to achieve this investment objective, the Fund will seek to track the performance of the Index, before the deduction of the TER and other Fund expenses, as further described under "*Fees and Expenses*" in the Prospectus. It will do so by investing, as far as possible and practicable, in the Index Securities, in the same proportions as their weightings in the Index.

Accordingly, the Fund may have exposure to or invest directly up to 20% of its Net Asset Value in shares issued by the same body, which limit may be raised to 35% for a single issuer in exceptional market conditions, including (but not limited to) circumstances in which such issuer occupies a dominant market position.

The Index is designed to measure the performance of certain companies involved in the healthcare technology industry. The companies included in the Index derive a proportion of their revenues from the field of healthcare technology and are selected in accordance with the ROBO Global® Industry Classification methodology.

Index Securities are assigned a score which is a measure of a company's revenue, investment exposure and market positioning in the healthcare technology industry, based on research conducted by ROBO Global® LLC (the "**Score**"). Companies whose Score is greater than or equal to 50, and who meet all other eligibility requirements as set out above, are eligible for inclusion in the Index.

The Index excludes companies that fail to meet certain market capitalisation and daily trading thresholds or adhere to the ROBO Global ESG Policy which is available here. Further detail in relation to the exclusions applied has been set out in the Annex.

PROFILE OF A TYPICAL INVESTOR

It is expected that investors in the Fund will be informed investors who: (i) have taken professional advice and who understand (and are able to bear) the risk of losing their investment; and (ii) can accept the levels of risks associated with investing in global equity markets, in particular in healthcare technology companies.

RISK FACTORS

Investors are referred to "Risk Factors" and Schedule II of the Prospectus and should consider all relevant risk factors prior to investing in the Fund. Investors should consider, in particular those relating to Shares, Index Tracking-Related Risks, Equity Risk, Sustainability Risks, Healthcare Technology Companies Risk, Micro, Small and Mid-Capitalisation Companies Risk and Risks Associated with Investment in China.

INDEX DISCLAIMER

The Fund is not sponsored, promoted, sold or supported in any other manner by ROBO Global® LLC or Solactive AG (the "**Index Parties**") nor do the Index Parties offer any express or implicit guarantee or assurance either with regard to the results of using the Index and/or Index trademark or the Index price at any time or in any other respect. The Index is calculated and published by Solactive AG. The Index Parties use their best efforts to ensure that the Index is calculated correctly. Irrespective of its obligations towards the Company, the Index Parties have no obligation to point out errors in the Index to third parties including but not limited to investors and/or financial intermediaries of the Fund. Neither publication of the Index by Solactive AG nor the licensing of the Index or Index trademark by ROBO Global® LLC for the purpose of use in connection with the Fund constitutes a recommendation by the Index Parties to invest capital in the Fund nor does it in any way represent an assurance or opinion of the Index Parties with regard to any investment in this Fund.

Pre-contractual disclosure for the financial products referred to in Article 9, paragraphs 1 to 4a, of Regulation (EU) 2019/2088 and Article 5, first paragraph, of Regulation (EU) 2020/852

Sustainable investment means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

The **EU Taxonomy** is a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities.** That Regulation does not include a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not.

Sustainability indicators measure how the sustainable objectives of this financial product are attained.

Product name:
L&G Healthcare Technology & Innovation UCITS ETF

Legal entity identifier:
213800J61B1UV4KX2A50

Sustainable investment objective

Does this financial product have a sustainable investment objective?

- [X] **Yes**
- [ ] **No**

- [ ] It will make a minimum of **sustainable investments with an environmental objective:** __%
  - [ ] in economic activities that qualify as environmentally sustainable under the EU Taxonomy
  - [ ] in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
- [X] It will make a minimum of **sustainable investments with a social objective:** 90%

- [ ] It **promotes Environmental/Social (E/S) characteristics** and while it does not have as its objective a sustainable investment, it will have a minimum proportion of __% of sustainable investments
  - [ ] with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy
  - [ ] with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
  - [ ] with a social objective
- [ ] It promotes E/S characteristics, but **will not make any sustainable investments**

What is the sustainable investment objective of this financial product?

The sustainable investment objective of the Fund is to provide exposure to the global healthcare technology industry. The Fund seeks to achieve its investment objective by tracking the performance of the ROBO Global® Healthcare Technology and Innovation Index TR (the "Index"). The Index is a reference benchmark that has been designated for the purpose of attaining the sustainable investment objective of the Fund.

What sustainability indicators are used to measure the attainment of the sustainable investment objective of this financial product?

1. The proportion of the Index exposed to companies not in accordance with the exclusionary criteria set out below;
2. Exposure to companies in accordance with the sustainable theme set out below.

Principal adverse impacts are the most significant negative impact of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anticorruption and anti-bribery matters.

How do sustainable investments not cause significant harm to any environmental or social sustainable investment objective?

The Fund applies the following exclusions through tracking the Index that excludes companies that:

• are non-compliant with the UN Global Compact,
• are associated with a controversy (i.e. companies that have been involved in events that have a severe impact on the environment and society, posing serious business risks to the company),
• are involved in the production or retail of tobacco, or are a related product/service,
• are involved in military contracting weapons or related products,
• are directly involved or indirectly involved through corporate ownership, in controversial weapons,
• are involved in thermal coal extraction, power generation or supporting products/services, and
• are involved in the production of unconventional and conventional oil and gas.

Through the application of the above exclusions it is ensured that the investments held by the Fund do not significantly harm any environmental or social objectives

How have the indicators for adverse impacts on sustainability factors been taken into account?

The Investment Manager assessed the Index against all sustainability indicators outlined in Table 1 of Annex I of Commission Delegated (EU) 2022/1288 (the "SFDR Level 2 Measures") and a majority of them are taken into account directly or indirectly by application of the above-listed exclusions. A direct approach occurs where an exclusionary screen incorporates, in its methodology, the metric defined in Table 1 of Annex I of the SFDR Level 2 Measures relating to the relevant sustainability indicator. The indirect approach will incorporate different metrics that are not defined in Table 1 of Annex I of the SFDR Level 2 Measures but associated with the sustainability indicators, such as norms-based or controversy screens to exclude issuers involved in violations. It should be noted that a small subset of sustainability indicators is not directly or indirectly mapped to the above-listed exclusions following consideration of their appropriateness to the Fund's investment strategy. The rationale for this may include inadequate data quality or coverage, or limited relevance to the Fund's eligible investment universe.

How are the sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights?

The Fund's sustainable investments are aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights through the application of the sustainability-related investment strategyused to attain the sustainable investment objective. In particular, the Index is designed to comply with international norms and standards, including the UN Global Compact principles and excludes companies that are associated with a controversy (i.e. companies that have been involved in events that have a severe impact on the environment and society, posing serious business risks to the company).

Accordingly, the Fund's investments aim to indirectly follow the UN Guiding Principles on Business and Human Rights, as well as the OECD Guidelines for Multinational Enterprises.

Does this financial product consider principal adverse impacts on sustainability factors?

X Yes, the Fund considers principal adverse impacts on sustainability factors. The Investment Manager takes the adverse sustainability indicators listed in Table 1 of Annex I of the SFDR Level 2 Measures into account, except for a small subset of indicators as explained above. The Fund considers principal adverse impacts, that are identified using the above-mentioned indicators, by tracking the Index that employs the sustainability-related investment strategy outlined below in line with its methodology.

For example, the Fund uses the 'Violations of UN Global Compact principles and Organisation for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises' indicator (indicator 10 of Table 1 of Annex I of SFDR) to identify principal adverse impacts relating to social matters set out in the UN Global Compact principles and then considers and takes actions in relation to principal adverse impacts identified through tracking the Index that excludes companies that violate such principles.

Further information on how the Manager and the Investment Manager consider principal adverse impacts on an entity level can be found in the Sustainability Policy which is available on LGIM's website. Reporting on principal adverse impacts on sustainability factors will be made available in the annual report of the Fund.

No

What investment strategy does this financial product follow?

The Fund follows the following sustainability-related investment strategy by tracking the Index:

• **Sustainable Theme**: The Index is comprised of companies that are actively engaged in the healthcare technology value-chain which seek to contribute to increased efficiency and effectiveness in healthcare and promote advancements and innovation in the healthcare industry.

• **ROBO Global ESG Policy**: The Index excludes investments in companies that fail to adhere to the ROBO Global ESG Policy. Following critical observations, the Index provider excludes companies that it believes do significant harm to environmental, social, and governance objectives. Each issuer within the investment universe of the Index is evaluated for the following metrics: i) the ESG risks that companies are exposed to and the risks that their activities could result in principal adverse impacts on sustainability factors, ii) the alignment of companies with international norms and standards, including the UN Global Compact principles, iii) involvement in harmful activities such as weapons and arms, tobacco, thermal coal-related activities, unconventional and conventional oil and gas-related activities, power generation and animal testing, and iv) economic activities contributing to the theme.

The Index Provider evaluates ESG factors using a combination of internal research, regular interaction with index member companies, as well as support from leading ESG research providers to ensure they comply with all aspects of the ROBO Global ESG Policy.

The Investment strategy guides investment decisions based on factors such as investment objectives and risk tolerance.

Good governance practices include sound management structures, employee relations, remuneration of staff and tax compliance.

What are the binding elements of the investment strategy used to select the investments to attain the sustainable investment objective?

The Fund aims to track the Index in accordance with its investment policy. As a result, the investment strategy set out above is binding on the investment decision-making process of the Fund.

What is the policy to assess good governance practices of the investee companies?

The Investment Manager ensures that the investee companies in which the Fund invests follow good governance practice by tracking an index that excludes companies that (i) fail to meet globally accepted norms and standards relating to governance matters, or (ii) are involved in incidents with negative governance implications. As part of its due diligence the Investment Manager assessed the Index to ensure compliance with these requirements.


In addition, the Investment Manager also integrates the principles of good governance practices into its stewardship and engagement approach by setting expectations with investee companies' management regarding good governance practices; actively engaging with the investee companies; utilising its voting rights; and supporting policymakers and legislators to ensure there is strong regulation and standards.

What is the asset allocation and the minimum share of sustainable investments?

Asset allocation describes the share of investments in specific assets.

The Fund will invest at least 90% of its portfolio in investments that qualify as sustainable (#1), all of which provide direct exposure to investee companies. The Fund will invest at least 0% of its portfolio in environmentally sustainable investments and at least 90% of its portfolio in socially sustainable investments. The actual level of environmentally and socially sustainable investments held by the Fund will always equate to at least the minimum proportion of sustainable investments of the portfolio outlined above. Some of the sustainable investments may be considered to contribute to both environmental and social objectives. The remaining portion of investments are not used to meet the sustainable investment objective and will fall under #2 Not sustainable

Taxonomy-aligned activities are expressed as a share of:
- **turnover** reflecting the share of revenue from green activities of investee companies
- **capital expenditure** (CapEx) showing the green investments made by investee companies, e.g. for a transition to a green economy.
- **operational expenditure** (OpEx) reflecting green operational activities of investee companies.



#1 Sustainable covers sustainable investments with environmental or social objectives.

#2 Not sustainable includes investments which do not qualify as sustainable investments.

How does the use of derivatives attain the sustainable investment objective?

The Fund does not make use of derivatives to attain the sustainable investment objective.

To what minimum extent are sustainable investments with an environmental objective aligned with the EU Taxonomy?

The Fund does not invest a minimum amount in economic activities that qualify as environmentally sustainable under the Taxonomy Regulation.

To comply with the EU Taxonomy, the criteria for **fossil gas** gas include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For **nuclear energy** energy, the criteria include comprehensive safety and waste management rules.

Enabling activities directly enable other activities to make a substantial contribution to an environmental objective.

Transitional activities are activities for which low-carbon alternatives are not yet available and among others have greenhouse gas emission levels corresponding to the best performance.

Does the financial product invest in fossil gas and/or nuclear energy related activities that comply with the EU Taxonomy[(1)]?


☐ Yes:

☐ In fossil gas ☐ In nuclear energy

☒ No

The two graphs below show in green the minimum percentage of investments that are aligned with the EU Taxonomy. As there is no appropriate methodology to determine the taxonomy alignment of sovereign bonds*, the first graph shows the taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomyalignment only in relation to the investments of the financial product other than sovereign bonds.


1. Taxonomy-alignment of investments **including sovereign bonds***



100%

- Taxonomy-aligned: Fossil gas
- Taxonomy-aligned: Nuclear
- Taxonomy-aligned (no fossil gas & nuclear)
- Non Taxonomy-aligned

2. Taxonomy-alignment of investments **excluding sovereign bonds***



100%

- Taxonomy-aligned: Fossil gas
- Taxonomy-aligned: Nuclear
- Taxonomy-aligned (no fossil gas & nuclear)
- Non Taxonomy-aligned

This graph represents up to 100.00% of the total Investments.

** For the purpose of these graphs, 'sovereigns bonds' consist of all sovereign exposures.*

What is the minimum share of investments in transitional and enabling activities?

The Fund does not invest a minimum share of investments in transitional and enabling activities within the meaning of the Taxonomy Regulation.

1 Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change ("climate change mitigation") and do not significantly harm any EU Taxonomy objectives -see explanatory note in the left hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.



are sustainable investments with an environmental objective that **do not take into account the criteria** for environmentally sustainable economic activities under the EU Taxonomy.



What is the minimum share of sustainable investments with an environmental objective that are not aligned with the EU Taxonomy?

The Fund does not invest in sustainable investments with an environmental objective.



What is the minimum share of sustainable investments with a social objective?

The minimum share of sustainable investments with a social objective is set at 90% of the Fund's portfolio.



What investments are included under "#2 Not sustainable", what is their purpose and are there any minimum environmental or social safeguards?

Other holdings may include cash, depositary receipts, money market funds and derivatives. Such investments may be used for investment purposes and efficient portfolio management. Derivatives may also be used for currency hedging for any currency hedged share classes. Environmental or social safeguards applied by the Index are only applied to instruments that are used to attain exposure to an Index constituent.

The Investment Manager considers ESG factors, including analysis from the relevant responsible investing methodologies as part of assessing the credit risk profile of its most significant counterparties. The Investment Manager has an internal control framework in place to consider and take appropriate action in the event that a significant counterparty fails to meet any minimum standards in respect of such ESG factors as defined by the Investment Manager.

Reference benchmarks are indexes to measure whether the financial product attains the sustainable investment objective.

Is a specific index designated as a reference benchmark to meet the sustainable investment objective?

Yes, the Index is designated as a reference benchmark.

How does the reference benchmark take into account sustainability factors in a way that is continuously aligned with the sustainable investment objective?

The Index is continuously aligned with the sustainable investment objective of the Fund by providing exposure to companies in accordance with the sustainability-related investment strategy described above. At each index rebalance, the selection criteria of the Index are applied to its constituents.

How is the alignment of the investment strategy with the methodology of the index ensured on a continuous basis?

The Fund invests, in a portfolio of securities that, as far as possible and practicable, consists of the component securities of the Index in similar proportions to their weightings in the Index.

How does the designated index differ from a relevant broad market index?

The Index is comprised of companies that are actively engaged in the healthcare technology value-chain which seek to contribute to increased efficiency and effectiveness in healthcare and promote advancements and innovation in the healthcare industry and therefore constitutes a smaller sub-set of a broad market index.

Where can the methodology used for the calculation of the designated index be found?

For further information in relation to the Index methodology please see:
https://www.roboglobal.com/robo-etfs

Where can I find more product specific information online?

More product-specific information can be found on the website: More product-specific information can be found on the website:
L&G Healthcare Technology & Innovation UCITS ETF - L&G Fund Centre